RWE is becoming an integral part of every healthcare organization’s transformation strategy to create a patient centric ecosystem. Increased patient engagement by all stakeholders, empowered by digital health solutions, has resulted in an explosion of Real World Data. This coupled with competitive pricing and rising drug development costs has further accelerated demand for RWE.
At the IMPACCT: RWE conference, Mu Sigma surveyed multiple leaders from 24 pharmaceutical and medical device companies on their organizations’ outlook for Real World Evidence. Survey questions were related to investment trends, focus areas and partnership models in RWE.
Read the survey report to find out the role RWE will play in building future-ready organizations.
